N-acetylcysteine for the treatment of cannabis dependence: working mechanisms

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519855-27-00

Enrollment

Registered

2025-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis dependence

Brief summary

Day 14 after study start.

Interventions

DRUGAcetylcysteïne Teva 600 mg

DRUGpoeder voor oraal gebruik

DRUGPlacebo Tablet 7mm Lichtenstein

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Day 14 after study start.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026